Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
A contingent of FDA employees placed on administrative leave back in April received terse final separation notices on July 14. Exactly how many CDRH staff ultimately were cut remains unclear, as the agency has quietly reinstated an array of previously dismissed employees over the past several months.
Buyer perception of business risk is a key determinant of successful medtech M&A, yet many companies fail to appreciate a potential acquirer’s perspective and how it perceives value. We outline the steps that leaders of earlier-stage companies can take to improve their understanding of what prospective acquirers truly want and thus increase the likelihood of a successful transaction. By Peter Meyer and Oded Ben-Joseph, Outcome Capital.
The EU issues a hotly anticipated guide on the “interplay” between the new AI Act and established device and diagnostic regulations. Excerpted from Pathways’ Picks June 25: Aligning the AI Act and MDR, EU Inches Toward MDSAP, Tarver Talks to Makary.